Ocugen, Washington University in Commercialization Deal for Covid Vaccine
By Chris Wack
Ocugen Inc. said Wednesday that it has entered into an exclusive license agreement with Washington University in St. Louis for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered Covid-19 vaccine in the U.S., Europe and Japan.
The vaccine is already authorized for emergency use in India, the company said.
Ocugen’s intranasal vaccine candidate is a recombinant, replication-deficient, adenovirus-vectored vaccine with a prefusion stabilized spike protein, it said.
The company said it intends to work closely with U.S. government agencies tasked with pandemic preparedness and response to initiate clinical trials and manufacture the intranasal vaccine, as well as pursue funding and investment options.
Ocugen shares were up 9% to $1.99 in premarket trading.
Write to Chris Wack at email@example.com
Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.